65,437 trials
Diabetes Mellitus · Metabolic Syndrome X · Hypercholesterolemia
Primary: Change in Plasma Thiobarbituric Acid Reactive Substance (TBARS) Levels — 2.1; 2.5 nmol/mL
Diabetes Mellitus, Type 1
Primary: Maximum Epinephrine Response (LBGI Groups) — 495; 217 pg/ml
Smoking Cessation · Schizophrenia
Primary: The Number of Subjects Who Quit Smoking From Weeks 5 to 8 — 3; 1 participants — p=0.632
Skin and Subcutaneous Tissue Bacterial Infections
Primary: The Early Clinical Response Rate — 283; 276 participants
Diabetes Mellitus, Type 1
Primary: Postprandial Glucose Excursion — 17.23; 14.47 milligrams per deciliter (mg/dL) — p=0.3217
Breast Cancer · Stage I Breast Cancer · Stage II Breast Cancer
Primary: Number of Participants With Adverse Events — 17 participants
Conditions in T74.31 or T76.31
Primary: Soft and Hard Tissue Landmarks Movement — 0.95; -0.5; -0.95; -0.32 mm — p=0.098
Continuous Methamphetamine Abuse
Primary: Self-report Effects of High. — 0; 0; 0; 0 units on a scale
Myelodysplastic Syndromes
Primary: Rate of Complete Remission (CR) and Partial Remission (PR) — 5; 1 participants
Rectal Carcinoma
Primary: Rate of Tumor Downstaging Compared With Historical Controls. — 64.4; 64.5 percentage of participants
Leukemia · B-cell Leukemia · Chronic Leukemia
Primary: Number of Subjects Maintaining Partial Response (PR) or Complete Response (CR) — 17 participants
Asthma
Primary: Percentage Change From Baseline (for Each Treatment Cycle) in Exhaled Nitric Oxide (eNO) — 36.65; 45.31; 54.58 Percentage change in eNO
Liposarcoma · Leiomyosarcoma
Primary: Time to Progression- Independent Review — 3.7; 2.3 months — p=0.0302
Cocaine-Related Disorders
Primary: Weekly Cocaine Use — 1.1; 1.3 days
Non-Hodgkin's Lymphoma · Diffuse Large Cell Lymphoma · Mantle Cell Lymphoma
Primary: Event-free Survival (EFS) — 83 percentage of not experiencing EFS event